SCNI · Scinai Immunotherapeutics Ltd.

Summary

Scinai Immunotherapeutics Ltd. executed a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., extending the option conditions deadline to August 31, 2026, and option exercise period to September 30, 2026, and submitted a revised €12 million non-dilutive FENG SMART Path application for an integrated €15 million R&D program for PC111. The funding, if awarded, would support advancement through human proof of concept while preserving balance sheet flexibility.

Key takeaways

• Executed Second Amendment to Binding Option Agreement with PinCell S.r.l.
• Option conditions fulfillment deadline extended to August 31, 2026
• Option exercise period extended to September 30, 2026
• Submitted revised FENG SMART Path application for €12 million (80% of €15 million R&D program)
• Application supports PC111 development for pemphigus vulgaris and SJS/TEN through human proof of concept
• Funding decision expected within 3-4 months